The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

Dec. 25, 2024 — A new method of scanning lungs is able to show in real time how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

National Jewish Health (previously National Jewish Medical and Research Center) is a research institute located in Denver, Colorado specializing in respiratory, immune and allergic research and ...